Research programme: androgen receptor antagonists - Serometrix
Alternative Names: SX-ARPCLatest Information Update: 28 Aug 2020
At a glance
- Originator Serometrix
- Class Antineoplastics
- Mechanism of Action Androgen receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Prostate cancer
Highest Development Phases
- No development reported Prostate cancer
Most Recent Events
- 28 Aug 2020 No recent reports of development identified for research development in Prostate-cancer in USA
- 12 Jul 2016 Research programme: androgen receptor antagonists - Serometrix is available for licensing as of 12 Jul 2016. http://www.serometrix.com/
- 12 Jul 2016 Early research in Prostate cancer in USA (unspecified route)